Trials / Completed
CompletedNCT00828165
A Safety Study of ARRY-300 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
This is a Phase 1 study, involving a 1-day dosing period (up to 3 dosing periods per subject), designed to test the safety of investigational study drug ARRY-300 in healthy subjects. Approximately 12 healthy subjects from the US will be enrolled in this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ARRY-300, MEK inhibitor; oral | single dose, escalating |
| DRUG | Placebo | matching placebo |
Timeline
- Start date
- 2009-01-01
- Primary completion
- 2009-04-01
- Completion
- 2009-04-01
- First posted
- 2009-01-23
- Last updated
- 2020-10-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00828165. Inclusion in this directory is not an endorsement.